Puretech Health Share Discussion Threads

[edwardt] 05/5/2022 11:28

where do you think they got that figure from? you should send them an invoice. lol

[lendmeafiver] 05/5/2022 10:37

Well I got that one right!

lendmeafiver26 Apr '22 - 08:33 - 1452 of 1456
Share buyback would be best whilst the share price is at these levels, given excess cash they should start now with say USD50m.

[w1lbur01] 05/5/2022 09:58

Back in this today after the Rns

[ohisay] 27/4/2022 04:04

On the face of it, there was nothing in the results to justify further shorting the shares. PureTech’s pipeline spans a broad range of products from cancer treatments that target hard-to-treat solid state tumours, irritable bowel syndrome, long covid sufferers and others to treat pulmonary disorders. All, in one way or another, are based on monoclonal antibody technology. Management says that currently 13 of the company’s 27 drug candidates are in clinical trials, with two products cleared for marketing by the Food and Drug Administration – Plenity and EndeavorRx.

The increase in candidates in clinical trials will have a direct impact on costs and management acknowledges that the company’s capital requirements will increase substantially as its programmes mature. However, it has a cash runway expected to last through to 2025 without any need for dilutive fundraising. It has also been selling shares in subsidiary companies. For example, it sold two tranches of shares worth $218mn (£171mn) in its Karuna subsidiary in 2021 to generate capital.

PureTech will continue to burn through cash until more of its products reach the partnering stage for larger pharma companies. At first sight, the pipeline looks very broad, but the focus on monoclonal antibodies gives it a certain specialisation. The company is well funded for several more years and the value case for the shares has been strengthened by the general fall in sector valuations. Buy.

[lendmeafiver] 26/4/2022 09:34

At the current share price the company could buy back say half of invescos holding now.

[edwardt] 26/4/2022 08:40

yeah - buyback over dividend would get my vote. that said, i would prefer a change in strategic shareholder at the top of the register. Invesco are probably weak holders given internal flows. Inmy mind, it would be better to get a large pharma as a key shareholder who may buy out the whole of parts of the business.

[lendmeafiver] 26/4/2022 08:33

Share buyback would be best whilst the share price is at these levels, given excess cash they should start now with say USD50m.

[lendmeafiver] 26/4/2022 08:30

will also aim to return a portion of the proceeds we may generate from either (1) the monetization of equity interests in our Founded Entities, (2) the receipt of potential royalty and sublicense income, and/or (3) other sources of proceeds such as strategic partnerships, to shareholders through various mechanisms, including share buybacks or special dividends.

[lendmeafiver] 22/4/2022 14:18

Results next week, there must be some comment made with respect to this ludicrous share price.

[lendmeafiver] 13/4/2022 20:32

Yep, is this still just a matter of waiting for the major shareholder to drop below 20%, then recovery?

[edwardt] 13/4/2022 18:38

Another great one just released too!

[edwardt] 13/4/2022 15:28

the latest announcements all look great and offer huge potential but jam tomorrow simply gets ignored atm.

[edwardt] 13/4/2022 15:27

getting smashed on this. i guess all long duration equities are in the same boat!

[lendmeafiver] 28/3/2022 11:32

I missed this bit of news earlier this year, all free upside:

pharmaphorum.com/news/puretech-challenges-roches-esbriet-in-head-to-head-ipf-trial/

[lendmeafiver] 16/3/2022 16:56

Certainly found some real support now, eg 75,000 share purchase today, I’m expecting it to be back in the 250-300 range soon.

[edwardt] 11/3/2022 12:28

finally a better day. it strikes me this company has f'all to do with events in europe so should catch a bid now given the clear markers for value creation we should see over the year. also the notion that funding will be harder to attain is a mute point for this company given cash on balance sheet....

[lendmeafiver] 10/3/2022 10:03

Possibly, hence no director buying at this bargain price.

[edwardt] 10/3/2022 09:44

or they use it as leverage to get a buyer with more patience to take this private at a considerable premium to current share price

[lendmeafiver] 09/3/2022 23:45

The Market Cap in London is so cheap vs Cash and Near Cash you get so much effectively for free here in my view, I purchased a fair few at 179p today, never thought a year ago I would have had that opportunity, not far off the original IPO now.

Would be good to see a certain shareholder go below 20%.

[rambutan2] 09/3/2022 22:40

As a reminder of what you are getting in a share of PRTC, it's worth looking through the last eight pages of the latest corp presentation ie pgs 81-88. And then there's approx $450m ie £340m cash on the balance sheet. Mkt cap at close today was £520m.

[lendmeafiver] 07/3/2022 22:10

Surprised Bharatt Chowrira hasn’t purchased more at these prices.

[edwardt] 23/2/2022 15:26

invesco clearly not helping. i would take the view this is more about risk and fund flows than a negative view on prtc.

[lendmeafiver] 18/2/2022 17:01

Well I bought some more this afternoon. Same old seller.

[lendmeafiver] 18/2/2022 15:29

Yet no reflection here, in fact a negative correlation, crazy valuation in London in my view.